{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"142.6","value":"-20.9"},{"groupId":"OG001","spread":"118.4","value":"50.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"description":"Best percentage change from baseline in PSA level was defined as the maximum percent decrease at any time post-baseline, including only patients with a baseline value and at least one non-missing post-baseline value (scheduled and unscheduled).","dispersionType":"Standard Deviation","groups":[{"description":"Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used","id":"OG000","title":"Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"},{"description":"Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator","id":"OG001","title":"Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone"}],"paramType":"MEAN","populationDescription":"PFS Full Analysis Set (PFS-FAS). Only participants with evaluable post-baseline and baseline samples were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From date of randomization till 30 days safety fup, assessed up to approximately 32 months (Primary Analysis cut-off date = 27-Jan-2021)","title":"Best Percentage Change From Baseline in Prostate-specific Antigen (PSA) Level","type":"SECONDARY","unitOfMeasure":"Percentage change"}